---
title: "SMOC's net profit for the year 2024 is approximately 6.5611 million yuan, turning a profit from a loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/229931368.md"
description: "SMOC released its 2024 annual performance preliminary report, with operating revenue of approximately 382 million yuan, a year-on-year increase of 4.20%. The company achieved a net profit of approximately 6.5611 million yuan, successfully turning a profit. Although there is still a net loss of 15.5207 million yuan after deducting non-recurring gains and losses, the rapid growth of overseas market revenue and strong demand from domestic research clients have contributed to performance improvement"
datetime: "2025-02-27T14:17:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/229931368.md)
  - [en](https://longbridge.com/en/news/229931368.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/229931368.md)
generator: "portal-rs"
---

# SMOC's net profit for the year 2024 is approximately 6.5611 million yuan, turning a profit from a loss

According to the Zhitong Finance APP, SMOC (688265.SH) disclosed its performance report for the year 2024, with operating revenue of approximately 382 million yuan, a year-on-year increase of 4.20%; net profit attributable to the parent company's owners was approximately 6.5611 million yuan, achieving a turnaround from loss to profit; net loss attributable to the parent company's owners, excluding non-recurring gains and losses, was approximately 15.5207 million yuan; basic earnings per share were 0.09 yuan.

During the reporting period, the company's operating revenue saw slight growth. On one hand, domestic research customers had good demand, and revenue from the research side grew steadily, but the investment and financing environment in the domestic biopharmaceutical industry has not yet shown significant recovery, leading to a slight decline in revenue from the industrial side; on the other hand, the company actively expanded overseas markets, with overseas business revenue growing rapidly. At the same time, the company continued to strengthen the management of production costs, R&D expenses, and customer collections. Additionally, non-recurring gains and losses such as financial investment income and government subsidies increased year-on-year, allowing the company to achieve a turnaround from loss to profit

### Related Stocks

- [688265.CN](https://longbridge.com/en/quote/688265.CN.md)
- [399441.CN](https://longbridge.com/en/quote/399441.CN.md)

## Related News & Research

- [13:42 ETBOLT ON Technology Named a 2026 Top Workplace, Earns Eight Culture Excellence Awards from Energage](https://longbridge.com/en/news/297548641.md)
- [BE Semiconductor Industries NV (OTCMKTS:BESIY) Short Interest Update](https://longbridge.com/en/news/297474065.md)
- [REG - AstraZeneca PLC - AstraZeneca completes agreement for Zegfrovy](https://longbridge.com/en/news/297603898.md)
- [Presurance Holdings director Timothy Lamothe sells 2,478 common shares worth $16,140.48](https://longbridge.com/en/news/297539334.md)
- [Embassy Bancorp CEO David M. Lobach Jr acquires $2,230 of common shares](https://longbridge.com/en/news/297538223.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**